Mind as an immunomodulator

Czech version

Authors: Cyril Höschl ^1,2; Jiří Horáček ^1,2
Authors‘ workplace: Národní ústav duševního zdraví, Klecany ¹; 3. LF UK, Praha ²
Published in: Vnitř Lék 2016; 62(Suppl 4): 36-41
Category: Reviews

Overview

Review paper highlights the connection between psyche and the body’s immune defense mechanisms and summarizes new findings on the relations between nervous and immune systems. The article also briefly describes the outcome of authors’ own original works on the relationship between infections and schizophrenia, and their notice about possible immunomodulatory effects of antipsychotics

Key words:
antipsychotics – immunity – infection – inflammation – mind – pain – schizophrenia

Sources

1. Baumeister D, Russell A, Pariante CM et al. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol 2014; 49(6): 841–849. Dostupné z DOI: <http://dx.doi.org/10.1007/s00127–014–0887-z>.

2. Höschl C, Horáček J. Nové poznatky o aripiprazolu jako výzva k hledání dalších antipsychotických modalit. Psychiatrie 2016; 20(1): 50–54.

3. Kubešová A, Tejkalová H, Syslová K et al. Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology. PLoS One 2015; 10(1): e0115439. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0115439>.

4. Ida T, Hara M, Nakamura Y et al. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 432(3): 232–236. Dostupné z DOI: <http://dx.doi.org/10.1016/j.neulet.2007.12.047>.

5. Miller AH, Haroon E, Raison CL et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013; 30(4): 297–306. Dostupné z DOI: <http://dx.doi.org/10.1002/da.22084>.

6. Zunszain PA, Anacker C, Cattaneo A et al. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuro-Psychopharmacology Biol Psychiatr 2011; 35(3): 722–729. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pnpbp.2010.04.011>.

7. Zunszain PA, Anacker C, Cattaneo A et al. Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012; 37(4): 939–949. Dostupné z DOI: <http://dx.doi.org/10.1038/npp.2011.277>.

8. Vonka V, Horáček J. Indolamin 2,3-dioxygenáza v onkologii a psychiatrii. Čas Lék čes 2015; 154(1): 3–10.

9. Horáček J, Flegr J, Tintěra J et al. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry 2012; 13(7): 501–509. Dostupné z DOI: <http://dx.doi.org/10.3109/15622975.2011.573809>.

10. Schwarcz R, Hunter CA. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid? Schizophr Bull 2007; 33(3): 652–653.

11. Wilke I, Arolt V, Rothermundt M et al. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246(5): 279–284.

12. Suzuki Y, Claflin J, Wang X et al. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int J Parasitol 2005; 35(1): 83–90.

13. Fernandes JF, Taketomi EA, Mineo JR et al. Antibody and cytokine responses to house dust mite allergens and Toxoplasma gondii antigens in atopic and non-atopic Brazilian subjects. Clin Immunol 2010; 136(): 148–156. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2010.02.019>.

14. Nagineni CN, Pardhasaradhi K, Martins MC et al. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 1996; 64(10): 4188–4196.

15. Silva NM, Rodrigues CV, Santoro MM et al. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect Immun 2002; 70(2): 859–868.

16. Pellicciari R, Rizzo RC, Costantino G et al. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl) benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. Chem Med Chem 2006; 1(5): 528–531.

17. Zwilling D, Huang SY, Sathyasaikumar KV et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145(6): 863–874. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2011.05.020>.

18. Wonodi I, Stine OC, Sathyasaikumar KV et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011; 68(7): 665–674. Dostupné z DOI: <http://dx.doi.org/10.1001/archgenpsychiatry.2011.71>.

19. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21(1): 9–19.

20. Borges S, Gayer-Anderson C, Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology 2013; 38(5): 603–611. Dostupné z DOI: <http://dx.doi.org/10.1016/j.psyneuen.2012.12.025>.

21. Baumeister D, Lightman SL, Pariante CM. The interface of stress and the HPA axis in behavioural phenotypes of mental illness. Curr Top Behav Neurosci 2014; 18: 13–24. Dostupné z DOI: <http://dx.doi.org/10.1007/7854_2014_304>.

22. Höschl C, Stárka L, Roth Z et al. A specific laboratory test for primary depression. Acta Univ Carol Med (Praha) 1985; 31(5–6): 347–364.

23. Marucha PT, Kiecolt-Glaser JK, Favagehi M. Mucosal wound healing is impaired by examination stress. Psychosom Med 1998; 60(3): 362–365.

24. Ebrecht M, Hextall J, Kirtley LG et al. Perceived stress and cortisol levels predict speed of wound healing in healthy male adult. Psychoneuroendocrinology 2004; 29(6): 798–809.

25. Upton D, Solowiej K, Hender C et al. Stress and pain associated with dressing change in patients with chronic wounds. J Wound Care 2012; 21(2): 53–54.

26. Barrientos RM, Sprunger DB, Campeau S et al. BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration. J Neuroimmunol 2004; 155(1–2): 119–126.

27. Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002; 7(Suppl 1): S46-S56.

28. Potvin S, Stip E, Sepehry AA et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63(8): 801–808.

29. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446–457. Dostupné z DOI: <http://dx.doi.org/1016/j.biopsych.2009.09.033>.

30. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology 2016; 233(9): 1575–1589. Dostupné z DOI: <http://dx.doi.org/10.1007/s00213–015–4044–5>.

31. Kubištová A, Horáček J, Novák T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012; 24(Suppl 1): S153-S156.

32. Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70(7): 663–671. Dostupné z DOI: <http://dx.doi.org/10.1016/j.biopsych.2011.04.013>.

33. Dahl J, Ormstad H, Aass HC et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014; 45: 77–86. Dostupné z DOI: <http://dx.doi.org/10.1016/j.psyneuen.2014.03.019>.

34. Raison CL, Demetrashvili M, Capuron L et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19(2): 105–123.

35. Sobiś J, Rykaczewska-Czerwińska M, Świetochowska E et al. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep 2015; 67(2): 353–359. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharep.2014.09.007>.

36. Horáček J, Tejkalová H, Novák T et al. The influence of a subanaesthetic dose of ketamine on circulating pro-inflammatory cytokines and serotonin in brain reply. Psychol Med 2011; 41(8): 1787–1789.

37. Raison C, Rutherford R, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31–41. Dostupné z DOI: <http://dx.doi.org/10.1001/2013.jamapsychiatry.4>.

38. Sommer IE, van Westrhenen R, Begemann MJ et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40(1): 181–191. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.1093/schbul/sbt139>.

39. Russell A, Ciufolini S, Gardner-Sood P et al. Inflammation and metabolic changes in first episode psychosis: preliminary results from a longitudinal study. Brain Behav Immun 2015; 49: 25–29. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbi.2015.06.004>.

40. Watkins LR, Goehler LE, Relton JK et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995; 183(1–2): 27–31.

41. Niijima A, Hori T, Aou S et al. The effects of interleukin-1 beta on the activity of adrenal, splenic and renal sympathetic nerves in the rat. J Autonom Nerv Syst 1991; 36(3): 183–192.

42. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405(6785): 458–462.

43. Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. J Exp Med 2012; 209(6): 1057–1068. Dostupné z DOI: <http://dx.doi.org/10.1084/jem.20120571>.

44. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140(6): 871–882. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2010.02.029>.

45. Diamond B, Huerta PT, Tracey K et al. It takes guts to grow a brain: Increasing evidence of the important role of the intestinal microflora in neuro- and immune-modulatory functions during development and adulthood. Bioessays 2011; 33(8): 588–591. Dostupné z DOI: <http://dx.doi.org/10.1002/bies.201100042>.

46. Wong CH, Jenne CN, Lee WY et al. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 2011; 334(6052): 101–105. <http://dx.doi.org/10.1126/science.1210301>.